United States Patent 8,871,779: Claim Scope, Validity Risks, Orange Book Status and Generic Entry Analysis
United States Patent No. 8,871,779 protects oxymorphone hydrochloride containing extremely low concentrations of 14-hydroxymorphinone, a degradation-related alpha,beta-unsaturated ketone impurity. The patent is narrower than a conventional oxymorphone composition patent because infringement depends on a quantitative impurity threshold. Claims 1 and 4 are the principal independent claims; claims 2 and 5 impose a tighter concentration limit, while claims 3 and 6 extend protection to pharmaceutical forms and formulations.
The patent does not broadly cover oxymorphone, oxymorphone hydrochloride, Opana, or extended-release oxymorphone formulations without satisfying the impurity limitations. Its commercial significance depends on whether a competing manufacturer’s oxymorphone hydrochloride necessarily falls below the claimed impurity thresholds and whether the patent was listed for the relevant FDA-approved product.
What does United States Patent 8,871,779 protect?
Patent 8,871,779 protects a purity-defined oxymorphone hydrochloride product. The central limitation is the presence of less than 0.001% of 14-hydroxymorphinone, with claims 2 and 5 reducing the threshold to less than 0.0005%.[1]
| Claim |
Claim type |
Protected subject matter |
Key limitation |
| 1 |
Independent composition claim |
Oxymorphone hydrochloride salt |
Less than 0.001% 14-hydroxymorphinone |
| 2 |
Dependent composition claim |
Oxymorphone hydrochloride of claim 1 |
Less than 0.0005% 14-hydroxymorphinone |
| 3 |
Dependent pharmaceutical-form claim |
Pharmaceutical acceptable form containing claim 1 material |
Incorporates claim 1 purity limitation |
| 4 |
Independent composition claim |
Oxymorphone hydrochloride within a defined morphinan-6-one formula |
Less than 0.001% HPLC-measured alpha,beta-unsaturated ketone |
| 5 |
Dependent composition claim |
Oxymorphone hydrochloride of claim 4 |
Less than 0.0005% 14-hydroxymorphinone |
| 6 |
Dependent formulation claim |
Pharmaceutical formulation containing claim 4 material |
Incorporates claim 4 impurity limitation |
The patent is therefore a product-composition patent, not primarily a process patent. A manufacturer may infringe even if it uses a different manufacturing process, provided the resulting oxymorphone hydrochloride satisfies the relevant impurity limitation.
How do claims 1 and 2 define the protected oxymorphone salt?
Claim 1 requires four material elements:
- A hydrochloride salt.
- The active compound is oxymorphone.
- The product contains less than 0.001% of 14-hydroxymorphinone.
- The claimed composition is the salt itself, rather than merely a formulation containing it.
Claim 2 narrows claim 1 by reducing the impurity level from below 0.001% to below 0.0005%. The lower threshold is one-half of the claim 1 threshold.
The use of “comprising” generally leaves the composition open to additional ingredients or impurities. It does not, however, eliminate the requirement that 14-hydroxymorphinone remain below the specified limit. A product containing other impurities may still fall within the claim if it meets the stated limitation.
What is 14-hydroxymorphinone?
14-Hydroxymorphinone is an oxidation or degradation-related impurity associated with oxymorphone chemistry. It contains an alpha,beta-unsaturated ketone structure. The impurity is relevant to both chemical quality control and toxicological assessment because low-level degradation products can affect the regulatory profile of an opioid active pharmaceutical ingredient.
The patent’s commercial objective is to capture a highly purified oxymorphone hydrochloride material with controlled levels of this impurity. The specification reportedly describes methods for obtaining oxymorphone hydrochloride with lower 14-hydroxymorphinone concentrations and improved pharmaceutical suitability.[1]
What is the scope of claim 4?
Claim 4 uses a generic morphinan-6-one framework but then specifies substituents that identify oxymorphone. The claim requires:
- Oxymorphone as the morphinan-6-one compound.
- A hydrochloride salt.
- Less than 0.001% of the corresponding alpha,beta-unsaturated ketone.
- Measurement by HPLC.
- Substituent definitions corresponding to oxymorphone, including hydroxy groups at the relevant positions and an N-methyl substituent.
Although claim 4 is drafted through a chemical formula, the stated substituents materially narrow it to oxymorphone hydrochloride. It is not a broad genus claim covering all morphinan-6-one compounds.
| Claim 4 limitation |
Practical meaning |
| Morphinan-6-one compound |
Defines the core opioid chemical structure |
| Oxymorphone |
Removes broader genus uncertainty |
| Hydrochloride salt |
Excludes free-base oxymorphone and other salts |
| Alpha,beta-unsaturated ketone impurity |
Targets 14-hydroxymorphinone |
| Less than 0.001% |
Creates a quantitative purity boundary |
| HPLC measurement |
Supplies the analytical measurement context |
Claim 4 is potentially stronger than claim 1 on measurement because it expressly identifies HPLC. It may also be more vulnerable if the patent does not adequately define the HPLC method, column, mobile phase, detection conditions, reference standard, sample preparation, or limit-of-quantitation requirements.
What formulations are protected by claims 3 and 6?
Claims 3 and 6 extend the patent to pharmaceutical products containing the qualifying oxymorphone hydrochloride.
Claim 3 depends on claim 1. A pharmaceutical acceptable form containing oxymorphone hydrochloride with less than 0.001% 14-hydroxymorphinone can fall within the claim.
Claim 6 depends on claim 4 and therefore requires the more specifically defined oxymorphone hydrochloride composition and the HPLC-based impurity limitation.
The formulation claims do not appear to require:
- Extended release;
- Immediate release;
- A specific tablet coating;
- A particular excipient;
- A specified dosage strength;
- A particular abuse-deterrent mechanism; or
- A particular route of administration.
That breadth helps the patent reach multiple dosage forms, but it also makes infringement dependent on the purity of the active ingredient used in the formulation.
What products could fall within the formulation claims?
Potentially covered products include:
- Immediate-release oxymorphone hydrochloride tablets;
- Extended-release oxymorphone hydrochloride tablets;
- Capsules containing qualifying oxymorphone hydrochloride;
- Granules, powders, or multiparticulate dosage forms;
- Hospital or extemporaneous pharmaceutical preparations; and
- Abuse-deterrent formulations containing the qualifying salt.
A finished dosage form would not avoid claims 3 or 6 merely because the impurity is diluted by excipients. The relevant issue is ordinarily the concentration in the oxymorphone hydrochloride material or the manner in which the claim defines the composition. Analytical protocols and claim construction would determine whether testing is performed on the API, the finished dosage form, or a reconstructed sample.
When does Patent 8,871,779 lose exclusivity?
Patent 8,871,779 was granted on October 28, 2014. Its earliest claimed priority date is September 30, 2008, and the patent family traces to an international filing directed to low-impurity oxymorphone hydrochloride.[1]
| Event |
Date |
| Earliest claimed priority |
September 30, 2008 |
| U.S. patent application family |
2009-era filing |
| U.S. patent publication |
2010-era publication |
| Grant of US 8,871,779 |
October 28, 2014 |
| Nominal 20-year term endpoint |
September 30, 2029 |
| Relevant post-grant adjustment |
Must be confirmed from USPTO Patent Term Adjustment data |
The practical nominal expiration date is September 30, 2029, subject to patent-term adjustment, terminal disclaimers, or other USPTO-recorded changes. A patent’s term runs from the applicable earliest nonprovisional filing date, not from the grant date, under the modern patent-term framework.[2]
The patent does not appear to have pediatric exclusivity associated with it. Any regulatory exclusivity for the underlying oxymorphone product is separate from the patent term.
What is the Orange Book status of Patent 8,871,779?
The Orange Book lists patents submitted by NDA sponsors for approved drug products and identifies patent information relevant to abbreviated new drug applications.[3] Oxymorphone products have included immediate-release and extended-release NDA products, including Opana and Opana ER.
The commercial relevance of Patent 8,871,779 depends on three questions:
- Whether Endo or an affiliated NDA holder submitted the patent to FDA.
- Whether FDA accepted the patent for listing against the relevant oxymorphone NDA.
- Whether the patent was listed with a product, formulation, or method-of-use code applicable to a generic applicant.
A purity-defined API patent can be relevant to Orange Book listing if it claims the active ingredient or a drug product containing the active ingredient. FDA listing does not decide infringement or validity. It creates a regulatory patent-information consequence for ANDA applicants, including potential Paragraph IV certification requirements under the Hatch-Waxman Act.[2][3]
Because Opana ER was withdrawn from the market at FDA’s request in 2017, the product’s commercial status and the patent’s regulatory relevance must be analyzed separately. FDA stated that the withdrawal request was based on public-health concerns involving opioid abuse and misuse, not a finding that the product was unsafe or ineffective when used as labeled.[4]
How strong is the patent estate for Patent 8,871,779?
The estate has meaningful strengths but also identifiable validity and enforcement risks.
Strengths
The patent has several features favorable to enforcement:
- It covers the drug substance rather than only a particular tablet design.
- The impurity threshold is quantitative and potentially testable.
- Claims 1 and 4 provide two independent claim structures.
- Claims 2 and 5 create a narrower fallback at less than 0.0005%.
- Claims 3 and 6 extend the protection to pharmaceutical forms and formulations.
- A process-around may be difficult if commercial oxymorphone hydrochloride manufacturing naturally produces very low impurity levels.
A competitor cannot avoid the patent simply by using a different salt-forming step if the final oxymorphone hydrochloride meets the claim limitations.
Weaknesses
The main risks concern claim construction, enablement, written description, indefiniteness, anticipation, and obviousness.
Measurement ambiguity
Claims 1 and 2 do not expressly identify HPLC in the text provided. Claim 4 does. A defendant may argue that the claims lack a sufficiently defined analytical method or that different validated HPLC methods produce materially different impurity results.
Prior-art purity disclosure
A prior-art oxymorphone hydrochloride batch could anticipate the claims if it disclosed, expressly or inherently, 14-hydroxymorphinone below the claimed threshold. Routine purification or standard pharmaceutical-quality controls could support an obviousness argument if the prior art taught removal of the impurity and provided a reasonable expectation of achieving the claimed level.
Inherent anticipation
Even if prior art did not report 14-hydroxymorphinone, a defendant could argue that a prior-art manufacturing process necessarily produced material below 0.001%. The result would depend on reproducibility, analytical sensitivity, and whether the prior-art process necessarily, rather than merely potentially, met the threshold.
Written-description and enablement issues
The claims cover any oxymorphone hydrochloride satisfying the impurity limit. If the specification provides only a limited number of purification techniques or examples, a challenger could argue that the full scope is not adequately supported or enabled.
Claim differentiation
Claims 2 and 5 establish a lower impurity threshold. A court may give claim 1 a broader construction, but the presence of the narrower dependent claims may limit arguments that claim 1 inherently requires the less-than-0.0005% level.
Which companies have challenged oxymorphone patent rights?
Generic oxymorphone competition has historically involved companies such as Actavis, Impax Laboratories, Roxane Laboratories, Sandoz and other ANDA applicants. Litigation concerning Opana and Opana ER included multiple Endo patent families, particularly patents directed to controlled release, formulation, and abuse-deterrent technology.
The available public record does not establish that every Opana-related ANDA case asserted Patent 8,871,779 specifically. Patent-by-patent review is necessary because Endo’s opioid litigation involved different patents, products, dosage forms, and settlement terms. A generic applicant could challenge this patent through:
- Paragraph IV certification;
- Inter partes review;
- Post-grant review, if statutory timing permitted;
- Declaratory judgment litigation; or
- Noninfringement based on impurity levels above the claimed threshold.
A Paragraph IV certification would trigger the statutory ANDA litigation framework if the patent were listed for the relevant NDA. The NDA holder generally has 45 days to file an infringement action, which can create a 30-month stay of ANDA approval under the Hatch-Waxman Act, subject to statutory exceptions.[2]
What generic launch risks exist?
The patent creates three principal launch scenarios.
| Scenario |
Technical position |
Commercial result |
| Product contains less than 0.001% impurity |
Likely literal infringement risk under claim 1 or 4 |
Paragraph IV challenge or delayed launch |
| Product contains less than 0.0005% impurity |
Higher exposure under claims 2 and 5 |
Stronger patent-holder position if claims survive |
| Product contains 0.001% or more impurity |
Potential noninfringement |
Must satisfy quality, safety and regulatory requirements |
A generic manufacturer may attempt to produce oxymorphone hydrochloride with a higher 14-hydroxymorphinone level to remain outside the claims. That strategy carries regulatory constraints. FDA approval requires the applicant to demonstrate that impurities are adequately controlled and that the proposed product meets applicable quality and safety standards. A process designed solely to remain above a patent threshold may create chemistry, manufacturing and controls problems.
The practical value of a noninfringement position therefore depends on whether the impurity can be increased without compromising API specifications, stability, toxicology, or finished-product approval.
What manufacturing and IP barriers does the patent create?
The patent’s principal barrier is analytical and process-based rather than formulation-based. A competing manufacturer must control:
- Oxymorphone oxidation;
- Formation of the alpha,beta-unsaturated ketone;
- Purification and crystallization conditions;
- Salt formation;
- Drying and storage;
- Stability under manufacturing and packaging conditions; and
- HPLC detection and batch-release specifications.
The patent may create a “purity floor” problem for generic manufacturers. If normal commercial processing consistently produces less than 0.001% 14-hydroxymorphinone, avoidance may require deliberate process changes. If those changes increase impurity levels beyond acceptable regulatory limits, the patent becomes a practical manufacturing barrier even if it is vulnerable legally.
How does Patent 8,871,779 compare with Opana formulation patents?
Patent 8,871,779 should be separated from patents covering controlled release or abuse deterrence.
| Patent category |
Primary protected feature |
Typical design-around |
| Low-impurity API patent |
Chemical purity of oxymorphone hydrochloride |
Increase impurity above threshold or invalidate patent |
| Controlled-release patent |
Release profile, matrix, coating or dosage architecture |
Use a different release mechanism |
| Abuse-deterrent patent |
Physical or chemical resistance to tampering |
Use alternative deterrent technology |
| Method-of-use patent |
Treatment of a specified condition or patient population |
Avoid patented indication or regimen |
| Manufacturing patent |
Synthetic, purification or crystallization process |
Use a different process |
A company may avoid a formulation patent while still infringing Patent 8,871,779 if it uses qualifying oxymorphone hydrochloride. Conversely, a company may avoid the low-impurity patent while infringing a separate controlled-release or abuse-deterrent patent.
What is the biosimilar risk for oxymorphone?
There is no biosimilar pathway for oxymorphone. Oxymorphone hydrochloride is a chemically synthesized small molecule, so competition proceeds through ANDAs or, in limited circumstances, 505(b)(2) applications rather than biosimilar applications under the Public Health Service Act.
The relevant competitors are generic-drug manufacturers, API suppliers and formulation companies. The patent does not create biologic interchangeability issues, reference-product exclusivity issues or biosimilar substitution questions.
What licensing and settlement issues affect the patent?
Publicly reported Opana litigation included settlements and commercial arrangements involving Endo and generic applicants. Those agreements may have included patent-specific or portfolio-wide terms, but settlement treatment cannot be inferred from litigation involving other Endo patents.
For Patent 8,871,779, the key diligence points are:
- Whether a settlement expressly covers the low-impurity patent;
- Whether the agreement permits an authorized generic;
- Whether launch rights are tied to a date earlier than September 2029;
- Whether the settlement covers immediate-release, extended-release or both products;
- Whether an API supplier is bound by the agreement; and
- Whether the agreement contains a no-challenge clause.
A settlement involving a controlled-release Opana patent does not necessarily resolve rights under Patent 8,871,779.
Key Takeaways
- Patent 8,871,779 is directed to oxymorphone hydrochloride with less than 0.001% 14-hydroxymorphinone.
- Claims 2 and 5 impose a stricter less-than-0.0005% threshold.
- Claims 3 and 6 extend the protection to pharmaceutical forms and formulations.
- Claim 4 expressly uses HPLC measurement and defines the relevant compound through oxymorphone-specific substituents.
- The nominal patent-term endpoint is September 30, 2029, subject to USPTO patent-term adjustment.
- The patent’s principal commercial value is its ability to cover the API used in otherwise differentiated oxymorphone formulations.
- Its principal validity risks are prior-art purity disclosures, inherent anticipation, analytical-method ambiguity and enablement.
- Generic applicants face a choice between challenging the patent and manufacturing oxymorphone hydrochloride above the claimed impurity threshold.
- Oxymorphone is a small-molecule drug and has generic, not biosimilar, competition.
- Opana’s 2017 market withdrawal does not by itself terminate the patent or resolve patent rights for other oxymorphone products.
FAQs About US Patent 8,871,779
Does Patent 8,871,779 cover oxymorphone free base?
No. The claims provided require oxymorphone hydrochloride. Oxymorphone free base and other oxymorphone salts fall outside the literal scope of those limitations.
Can a generic manufacturer avoid the patent by using a different HPLC method?
Not automatically. Claims 1 and 2 do not expressly include the HPLC limitation in the text provided, while claim 4 does. The outcome would depend on claim construction, the patent specification and the court’s determination of the appropriate analytical method.
Does the patent cover every Opana tablet?
No. A tablet must contain oxymorphone hydrochloride meeting the stated impurity limitation. The patent does not independently cover every oxymorphone tablet, every extended-release formulation or every Opana product.
Is an oxymorphone ANDA required to file a Paragraph IV certification?
Only if the relevant patent is listed in the FDA Orange Book for the reference product and the ANDA applicant seeks approval before the listed patent’s expiration. The certification requirement depends on the patent’s listing status and the product covered by the ANDA.
Can a manufacturer sell oxymorphone after September 2029 without addressing this patent?
Subject to any patent-term adjustment, terminal disclaimer or other enforceable right, the composition claims should no longer block launch after the applicable expiration date. Separate formulation, method-of-use, regulatory or manufacturing patents may still affect the product.
References
- United States Patent and Trademark Office. (2014). US Patent No. 8,871,779, oxymorphone hydrochloride having low levels of 14-hydroxymorphinone.
- United States Code. (2023). 35 U.S.C. §§ 154, 271(e), and 282; 21 U.S.C. § 355.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- U.S. Food and Drug Administration. (2017). FDA requests removal of Opana ER for risks related to abuse.
